61190-02-1

Basic information

• Product Name: Ethanamine, 2,2-diethoxy-N-(phenylmethylene)-
• CAS NO: 61190-02-1
• Molecular Formula: C13H19NO2
• Molecular Weight: 221.299
• Mol File: 61190-02-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Ethanamine, 2,2-diethoxy-N-(phenylmethylene)-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanamine, 2,2-diethoxy-N-(phenylmethylene)-(61190-02-1)
• EPA Substance Registry System: Ethanamine, 2,2-diethoxy-N-(phenylmethylene)-(61190-02-1)

Safety Data

• Hazardous Substances Data: 61190-02-1(Hazardous Substances Data)

Upstream product

• 6065-82-3 Ethyl diethoxyacetate 
• 61189-99-9 diethoxyacetamide 
• 100-52-7 benzaldehyde 
• 645-36-3 2,2-diethoxy-ethanamine 

Downstream Products

• 76143-77-6 (1-phenyl-ethylamino)-acetaldehyde diethylacetal 
• 61190-10-1 N-benzyl-N-(2,2-diethoxyethyl)amine 
• 100-52-7 benzaldehyde 
• 119-65-3 isoquinoline 
• 103157-55-7 N-(2,2-diethoxy-ethyl)-N-(4-methyl-benzhydryl)-N'-phenyl-urea 
• 102946-65-6 N-benzhydryl-N-(2,2-diethoxy-ethyl)-N'-phenyl-urea 
• 102453-84-9 N-(2,2-diethoxy-ethyl)-N'-phenyl-N-(1-phenyl-ethyl)-urea 
• 7661-37-2 1-propylisoquinoline 
• 7661-60-1 1-ethyl-isoquinoline 
• 1721-93-3 1-methylisoquinoline 
• 76143-79-8 (1-phenyl-propylamino)-acetaldehyde diethylacetal 
• 102320-91-2 benzhydrylamino-acetaldehyde diethylacetal 

Relevant articles and documents

Pomeranz-Fritsch Synthesis of Isoquinoline: Gas-Phase Collisional Activation Opens Additional Reaction Pathways

We have investigated the gas-phase production of isoquinoline by performing collisional activation on benzalaminoacetal, the first intermediate in the classic solution-phase Pomeranz-Fritsch synthesis of isoquinoline. We have elucidated the reaction pathw

ALPHA HELIX MIMETICS AND METHODS RELATING THERETO

Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a chemical library relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.